Commercializing cell and gene therapy operations now means protecting time-to-patient across constrained, exception-heavy patient journeys. The planning challenge sits in exception handling, scale-out capacity, treatment-center visibility and dynamic resource optimization, where Bluecrux Technology Binocs™ help teams connect decisions before delays reach the patient.
The market keeps moving. FDA maintains a current list of licensed cell and gene therapy products and notes continued rapid growth in CGT-related R&D, while ASGCT’s Q1 2026 report recorded two new approvals across gene, cell and RNA categories, fewer approvals than some earlier quarters, more regulatory de-risking and stronger advanced molecular therapy dealmaking. That progress puts more pressure on operations to manage patient-specific timing, constrained slots and late change.
CGT schedules can look manageable until a collection is delayed, a release date slips, a patient isn’t ready, or a treatment center loses a slot. To quote J. Andrew Case, Head of Supply Chain for Cell & Gene Therapies at Genentech/Roche: “Quite often, the happy path is not what’s followed when you’re trying to manage [manufacturing slots]… what’s really complicated is rescheduling… because if you miss one of those slots, you’ve missed it. There is no going back.”
Binocs brings resources, slots, dependencies, and schedule updates into one planning layer, so teams can assess a change against available staff, equipment, manufacturing capacity and release workload before the impact reaches the site. That turns rescheduling from a reactive scramble into a constrained planning decision, especially in time-critical autologous operations.
Conventional pharma growth can often be planned around bigger batches and broader distribution. Autologous CGT grows patient by patient, with each journey carrying its own timing, identity, chain of custody, manufacturing dependency, and treatment-center readiness. To quote J. Andrew Case again: “You can only scale out. You cannot scale up, at least when it’s fully autologous.”
Deloitte makes the same operational point from another angle, noting that many advanced therapies depend on patient-specific cellular material, near-real-time delivery, strict chain of identity and custody, and integrated cross-functional business models.
Binocs supports CGT teams with capacity planning, slot allocation and scenario planning built for patient-specific operations. Its CGT-focused capabilities include autologous therapy slot allocation and more granular capacity forecasting, helping planners understand where capacity is truly available before they commit a patient journey to the plan.
For CGT, customer experience shows up in the treatment center’s day. Sites need to know what is happening, what has changed, and what that change means for staff, rooms, patients and scheduling. This is a concrete challenge that can be overlooked during the pre-commercialization phase but which should be carefully planned for early-on, because treatment centers wil need granular visibility across multiple manuals, platforms, and bespoke processes. That means building cooperation and standardization into processes from Day One, so that the burden of interpretation isn’t placed on the people whose jobs are to save lives.
McKesson’s 2025 CGT report frames access barriers around geography, cost, coordination and commercialization, and states that scientific promise doesn’t automatically become patient access. Deloitte also argues that site onboarding and clinical operations need to become simpler and more standardized so more hospitals and clinics can deliver advanced therapies.
Not only does Binocs give treatment centers a practical way to book and view slots against real manufacturing availability but zero-code integration is core feature of the product. As a result, the full value of Binocs scheduling and planning can be seamlessly integrated with third party orchestration systems, meaning that clinical teams can plan apheresis appointments with greater confidence, in full alignment with production capacity, expected shipping time, and the wider operating plan.
Spreadsheets can capture a plan, but they’re a poor place to simulate a delayed collection, a manufacturing slot change, a release dependency and the treatment-center impact of each decision. Ultimately, while it is certainly extremely versatile and useful in certain contexts, Excel is very static and lacks the dimensionality and dynamism needed for forecasting, scenario planning, and capacity optimization.
Indeed, Deloitte specifically notes that CGT teams still suffer from an infgrastructure gap where tech systems lag behind the scientific advancements. That gap often shows up in disconnected planning tools, manual coordination, and limited ability to model scenarios across functions, making scalable, digitally integrated, end-to-end planning systems all the more vital.
Binocs moves CGT planning away from manual files and disconnected updates by connecting demand, resources, schedules and what-if scenarios in one environment. For teams still coordinating through Excel, calls and email, that means better visibility into workload, more reliable scenario planning and a clearer view of how each change affects the ability to protect time-to-patient.
Commercializing CGT means coordinating scarce resources around real patients, real slots, and real exceptions. Resource optimization belongs in the access model because time-to-patient depends on visibility before a delay becomes urgent.
Improving scheduling visibility and protect time-to-patient together
